Tags : secukinumab

Novartis Reports Results of Cosentyx (secukinumab) in Head to Head

Shots: The P-III EXCEED study involves assessing Cosentyx (300mg) vs Humira (adalimumab, 40 mg) in 800+ biologic-naïve patients with PsA for 52wks. The P-III EXCEED results: Cosentyx narrowly missed statistical significance for superiority in ACR 20 but showed significant advantages in PsA specific endpoints, observed in a pre-specified sensitivity analysis, no new safety signals were […]Read More

Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with

Shots: The approval is based on P-III CAIN457A2318 study results assessing Cosentyx (300/150 mg, q4w) vs PBO in 543 patients with moderate-to-severe plaque PsO. Additionally, P-III study in China assessed Cosentyx (300mg, q4w) in 10 Psoriasis patients P-III CAIN457A2318 study results: @12 wks. PASI 75/90 (97.7%, 87.8%/ 80.9%, 66.4%); @16wks. PASI 90 87.0%, well tolerated […]Read More